{"ok":true,"article":{"slug":"lutetium-lu-177-vipivotide-tetraxetan-approval-reshapes-the-treatment-landscape--ccadec24","title":"Lutetium Lu 177 Vipivotide Tetraxetan Approval Reshapes the Treatment Landscape for PSMA+ mHSPC","url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNTWJOaTRaUFdEWmlSZS03YjMwbWZ2eTdVWTNNZHNsZ3daVDF2V19jUEhDdURlNzFLVE9oUXU4SmtJeXBOSnlaVHBmaE9Gcll4eFZPczRLQVhqMGpKYTljWUdHY0VSN2ZaREJMM1hsNlVRU1dkLWJnNHY3T3E3bTVuUjlhUUJJZ3R0YlFtVUtIR19XT3BnalhCUVkwbGFzaWZ4ZF8zM3B3LW9HYTE4WWtZVVA5em5lSzY0TzliSm9uQng?oc=5&hl=en-US&gl=US&ceid=US:en","canonical":"https://www.aimode.news/article/lutetium-lu-177-vipivotide-tetraxetan-approval-reshapes-the-treatment-landscape--ccadec24","sourceName":"OncLive","summary":"Related coverage: Lutetium Lu 177 Vipivotide Tetraxetan Approval Reshapes the Treatment Landscape for PSMA+ mHSPC OncLive","category":"Health","image":null,"lang":"en","publishedAt":"2026-08-13T13:12:36+00:00","createdAt":"2026-08-13T13:30:13.033706+00:00"}}